ABVC BioPharma Announces Spin-Off of BioKey Subsidiary via Dividend Distribution to Shareholders

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced a planned spin-off of its wholly owned subsidiary BioKey (Cayman), Inc. through a pro rata dividend distribution of BioKey shares to ABVC shareholders. The move is intended to unlock the underlying value of its businesses and reward shareholders with direct participation in BioKey's future growth.

Subject to regulatory approvals, including the effectiveness of the Registration Statement on Form 10 by June 25, 2026, ABVC will distribute approximately 4.5 million Ordinary Shares of BioKey, representing about 15% of BioKey's outstanding shares, to shareholders of record as of July 24, 2026. The distribution is expected to be effective on August 3, 2026. Shareholders do not need to take any action, and no consideration is required. The shares will be issued in book-entry form through VStock Transfer, LLC.

BioKey is a nutraceutical and functional-supplement research, development, and manufacturing company operating as a fully integrated CRO and CDMO platform. Through its subsidiary BioKey, Inc. in California, it offers contract research, formulation development, cGMP manufacturing, regulatory support, and commercial supply services across Asia and North America. BioKey also plans to integrate artificial intelligence into its services.

Following the spin-off, BioKey intends to apply for its shares to be quoted on the OTC Markets, though no public trading market currently exists. ABVC's common stock will continue trading on Nasdaq under the symbol "ABVC."

Dr. Uttam Patil, ABVC's CEO, stated, "We believe the BioKey transaction provides an opportunity to highlight the underlying value of our businesses while maintaining our commitment to long-term shareholder value creation." The spin-off is part of ABVC's broader strategy to unlock value from its subsidiaries and technology platforms, including potential future separations.

ABVC BioPharma is a clinical-stage company with a pipeline of six drugs and one medical device under development, utilizing technology licensed from institutions like Stanford University and UCSF. The spin-off allows shareholders to directly benefit from BioKey's independent growth trajectory.

More details are available in the Information Statement accompanying the Form 10 filed with the SEC on June 22, 2026, accessible at http://www.sec.gov.